StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.95+0.10 (+3.33%)

Close on Nov 18, 2026Market cap $242.04MP/E –Yield –

Lexeo Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Lexeo Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $654.00K. For fiscal 2022 it was $654.00K.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$654.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$531.00K–

More Lexeo Therapeutics figures

See a number that looks wrong?